The MENA evidence gap for selected portfolios is becoming a commercial liability for drugmakers that could have been prevented at the design stage.
The post When Evidence Gap Becomes a Commercial Liability appeared first on MedCity News.
When Evidence Gap Becomes a Commercial Liability
